The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 58 formulations used for treatment of various ailments, including cardiac conditions, anxiety disorders, Hepatitis C and diabetes.
While the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 56 formulations, it has also capped the ceiling prices of two formulations, a notification on the regulator's website said.
The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.
The regulator has fixed the retail prices of drugs manufactured and marketed by various firms. The drugs include Sofosbuvir and Ledipasvir tablets used for treatment of hepatitis C.
It has also fixed the retail price of Teneligliptin Metformin tablet (Teneblu M Forte) used for treatment of diabetes.
The NPPA has capped the ceiling prices of Digoxin and Furosemide oral liquids.
The regulator is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
The NPPA implements and enforces the provisions of the Drugs (Prices Control) Order.
It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app